https://www.fda.gov/news-events/public-health-focus/expanded-access
This is worth a read.
I did a search on Alterity's website for the term 'expanded access' and nothing come up. So with no expanded access policy, it is my opinion that treatment will stop once the trial has concluded. And I don't recall any announcement stating that people have, or can, access ATH434 outside of any trial.
But please, fire off an e-mail to them, they may surprise me and state that they have such a policy, and that they have treated people outside of a trial.
Ann: Alterity Presents Data Describing Neuroprotection of ATH434, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.001(10.0%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.1¢ | 1.0¢ | $12.66K | 1.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 4352071 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 8220041 | 19 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |